Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 7230626, 8 pages
http://dx.doi.org/10.1155/2016/7230626
Research Article

Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers

1University of Medicine and Pharmacy, Tirgu Mureș, Gheorghe Marinescu 38, 540139 Mures, Romania
2University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca, 8 Victor Babeş, 400012 Cluj-Napoca, Romania
3Emergency County Hospital, Tirgu Mures, Gheorghe Marinescu 50, 540136 Mures, Romania

Received 13 April 2016; Revised 1 July 2016; Accepted 11 July 2016

Academic Editor: Vikram Kate

Copyright © 2016 Anca Negovan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Baigent, L. Blackwell, R. Collins et al., “Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials,” The Lancet, vol. 30, no. 9678, pp. 1849–1860, 2009. View at Google Scholar
  2. J. Cuzick, M. A. Thorat, C. Bosetti et al., “Estimates of benefits and harms of prophylactic use of aspirin in the general population,” Annals of Oncology, vol. 26, no. 1, pp. 47–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Sostres and A. Lanas, “Gastrointestinal effects of aspirin,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 7, pp. 385–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Hernández-Díaz and L. A. García Rodríguez, “Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications,” BMC Medicine, vol. 4, article 22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. L. Bhatt, J. Scheiman, N. S. Abraham et al., “ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,” Circulation, vol. 118, no. 18, pp. 1894–1909, 2008. View at Publisher · View at Google Scholar
  6. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. V. E. Valkhoff, M. C. J. M. Sturkenboom, and E. J. Kuipers, “Risk factors for gastrointestinal bleeding associated with low-dose aspirin,” Best Practice and Research: Clinical Gastroenterology, vol. 26, no. 2, pp. 125–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lanas and J. Scheiman, “Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 163–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Faul, E. Erdfelder, A. Buchner, and A.-G. Lang, GPower Version 3.1.9.2 [Computer Software], Universität Kiel, Kiel, Germany, 2014, http://www.softpedia.com/get/Science-CAD/G-Power.shtml.
  10. N. Kawamura, Y. Ito, M. Sasaki et al., “Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers,” BMC Research Notes, vol. 6, article 455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Nema, M. Kato, T. Katsurada et al., “Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease,” Journal of Gastroenterology and Hepatology, vol. 23, supplement 2, pp. S234–S236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. N. D. Yeomans, A. I. Lanas, N. J. Talley et al., “Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 9, pp. 795–801, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Shiotani, T. Sakakibara, Y. Yamanaka et al., “Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin,” Journal of Gastroenterology, vol. 44, no. 2, pp. 126–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Iwamoto, Y. Saito, A. Honda, and Y. Matsuzaki, “Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy,” World Journal of Gastroenterology, vol. 19, no. 11, pp. 1673–1682, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. C. J. Hawkey, I. Wilson, J. Næsdal, G. Långström, A. J. Swannell, and N. D. Yeomans, “Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users,” Gut, vol. 51, no. 3, pp. 344–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. S. Tang and F. K. L. Chan, “Mechanisms behind the increased vulnerability of the aging stomach to NSAID-related injury: perhaps not as simple as we may think,” Digestive Diseases and Sciences, vol. 58, no. 1, pp. 11–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Iijima, N. Ara, Y. Abe et al., “Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level,” Journal of Gastroenterology, vol. 47, no. 12, pp. 1290–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Sostres, C. J. Gargallo, and A. Lanas, “Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights,” World Journal of Gastroenterology, vol. 20, no. 28, pp. 9439–9450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. E.-L. Leung Ki and F. K. L. Chan, “Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice,” Best Practice and Research: Clinical Gastroenterology, vol. 26, no. 2, pp. 163–172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Lanas, E. Bajador, P. Serrano et al., “Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding,” The New England Journal of Medicine, vol. 343, no. 12, pp. 834–839, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. E. H. Fletcher, D. E. Johnston, C. R. Fisher, R. J. Koerner, J. L. Newton, and C. S. Gray, “Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 7, pp. 831–839, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Pilotto, M. Franceschi, M. G. Longo et al., “Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin,” Digestive and Liver Disease, vol. 36, no. 10, pp. 666–670, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Uemura, K. Sugano, H. Hiraishi et al., “Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: The Results from the MAGIC Study,” Journal of Gastroenterology, vol. 49, no. 5, pp. 814–824, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Shiotani, T. Sakakibara, Y. Yamanaka et al., “The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy,” Journal of Gastroenterology, vol. 44, no. 7, pp. 717–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Iijima and T. Shimosegawa, “Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury,” World Journal of Gastroenterology, vol. 21, no. 25, pp. 7709–7717, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Peleteiro, A. Bastos, A. Ferro, and N. Lunet, “Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage,” Digestive Diseases and Sciences, vol. 59, no. 8, pp. 1698–1709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Sporea, A. Popescu, M. Van Blankenstein et al., “The prevalence of helicobacter pylori infection in western Romania,” Romanian Journal of Gastroenterology, vol. 12, no. 1, pp. 15–18, 2003. View at Google Scholar · View at Scopus
  28. K. Okada, M. Inamori, K. Imajo et al., “Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients,” Hepato-Gastroenterology, vol. 56, no. 96, pp. 1665–1669, 2009. View at Google Scholar · View at Scopus
  29. C. J. Crooks, J. West, and T. R. Card, “Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding,” Gastroenterology, vol. 144, no. 7, pp. 1384–1393, 2013. View at Publisher · View at Google Scholar
  30. W. Ng, W.-M. Wong, W.-H. Chen et al., “Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease,” World Journal of Gastroenterology, vol. 12, no. 19, pp. 2923–2927, 2006. View at Google Scholar · View at Scopus
  31. T. Higuchi, R. Iwakiri, M. Hara et al., “Low-dose aspirin and comorbidities are significantly related to bleeding peptic ulcers in elderly patients compared with nonelderly patients in Japan,” Internal Medicine, vol. 53, no. 5, pp. 367–373, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Lanas, J. Fuentes, R. Benito, P. Serrano, E. Bajador, and R. Sáinz, “Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 4, pp. 779–786, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Serrano, A. Lanas, M. T. Arroyo, and I. J. Ferreira, “Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 11, pp. 1945–1953, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-F. Li, R. L. Y. Chan, L. Lu et al., “Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review),” International Journal of Molecular Medicine, vol. 34, no. 2, pp. 372–380, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Shimada, A. Nagahara, M. Hojo et al., “Upper gastrointestinal mucosal injury and symptoms in elderly low-dose aspirin users,” Gastroenterology Research and Practice, vol. 2015, Article ID 252963, 7 pages, 2015. View at Publisher · View at Google Scholar
  36. A. Moore, I. Bjarnason, B. Cryer et al., “Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm,” Clinical Gastroenterology and Hepatology, vol. 7, no. 11, pp. 1156–1163, 2009. View at Publisher · View at Google Scholar · View at Scopus